AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$4.52
−$0.18 (−3.73%) 3:58 PM ET
After hours$4.54
+$0.02 (+0.44%) 1:45 AM ET
Prev closePrevC$4.69
OpenOpen$4.65
Day highHigh$4.66
Day lowLow$4.46
VolumeVol249,400
Avg volAvgVol342,763
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$327.41M
P/E ratio
-1.43
FY Revenue
$63.50M
EPS
-3.15
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
BCYC
Bicycle Therapeutics plc
No AI report section text found yet for this symbol.
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
NVSBCYCPEPGPeptide Drug Conjugatestargeted drug deliveryoncologyclinical trialsmarket growth
Sentiment note
Identified as an emerging biotechnology firm actively developing novel peptide platforms and linker technologies to advance PDC therapeutics.
PositiveGlobeNewswire Inc.• Globe Newswire
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
Bicycle Toxin Conjugates (BTCs) are emerging as a novel targeted oncology technology, offering innovative peptide-based drug delivery with potential applications in cancer treatment and beyond, with early clinical trials showing promising results.
Company is leading BTC development, demonstrating pioneering efforts, proprietary platforms, and clinical expertise in a rapidly evolving therapeutic field
NeutralGlobeNewswire Inc.• Maxion Therapeutics
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
Maxion Therapeutics appointed Dr. Santiago Arroyo as a Non-Executive Director, bringing extensive clinical development expertise from roles at multiple pharmaceutical and biotech companies.
Mentioned as previous employer of Dr. Arroyo with no specific context
PositiveGlobeNewswire Inc.• Delveinsight
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.
The company's pipeline drug, BT8009, has received Fast Track Designation from the FDA for the treatment of previously treated locally advanced or metastatic urothelial carcinoma.
UnknownZacks Investment Research• Zacks Equity Research
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
BCYCTWST
UnknownZacks Investment Research• Nalak Das
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
LXRXPRMEBCYCCSTL
UnknownZacks Investment Research• Zacks Equity Research
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
BCYCBKD
UnknownZacks Investment Research• Zacks Equity Research
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
ENTXBCYCANVSALXO
UnknownZacks Investment Research• Zacks Equity Research
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BCYC
UnknownZacks Investment Research• Zacks Equity Research
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
BCYCOCGN
UnknownZacks Investment Research• Zacks Equity Research
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BCYC
UnknownZacks Investment Research• Zacks Equity Research
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BCYC
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
